Definitive Healthcare (NASDAQ:DH) Price Target Lowered to $3.00 at The Goldman Sachs Group

Definitive Healthcare (NASDAQ:DH) had its price objective decreased by analysts at The Goldman Sachs Group from $4.50 to $3.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price indicates a potential upside of 8.03% from the company’s previous close.

DH has been the topic of a number of other reports. Barclays cut their target price on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a research note on Monday. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Finally, Stephens began coverage on Definitive Healthcare in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 target price for the company. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Definitive Healthcare presently has an average rating of “Hold” and a consensus target price of $5.35.

Definitive Healthcare Trading Down 1.9 %

Definitive Healthcare stock opened at $2.78 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. Definitive Healthcare has a 1 year low of $2.58 and a 1 year high of $8.82. The firm’s 50-day moving average is $4.60 and its 200-day moving average is $4.47. The company has a market cap of $320.81 million, a P/E ratio of -0.89, a PEG ratio of 4.06 and a beta of 1.45.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). The business had revenue of $62.29 million during the quarter, compared to the consensus estimate of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. On average, equities analysts expect that Definitive Healthcare will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DH. Massachusetts Financial Services Co. MA raised its stake in Definitive Healthcare by 36.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock valued at $27,058,000 after purchasing an additional 1,626,813 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Definitive Healthcare in the 3rd quarter worth approximately $512,000. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Definitive Healthcare by 34.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 50,886 shares of the company’s stock worth $209,000 after purchasing an additional 12,946 shares in the last quarter. Barclays PLC increased its holdings in Definitive Healthcare by 318.8% in the 3rd quarter. Barclays PLC now owns 81,916 shares of the company’s stock valued at $366,000 after buying an additional 62,354 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Definitive Healthcare by 431.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 222,090 shares of the company’s stock valued at $993,000 after buying an additional 180,323 shares in the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.